{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:07:17Z","timestamp":1791493637709,"version":"4.3.4"},"reference-count":38,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008069","name":"University of California, San Francisco","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.euf.2025.06.007","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T15:36:40Z","timestamp":1754408200000},"page":"869-875","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Determining Optimal Patient Selection for High-intensity Focused Ultrasound for Prostate Cancer"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5378-7650","authenticated-orcid":false,"given":"Kevin","family":"Shee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Pace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew W.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet E.","family":"Cowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishvak","family":"Subramanyam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron","family":"Agapito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Samuel L.","family":"Washington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Cooperberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter R.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuto","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao G.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2025.06.007_b0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euf.2025.06.007_b0010","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/JU.0000000000002854","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2025.06.007_b0015","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1001\/jama.2019.20675","article-title":"Patient-reported outcomes through 5 years for active surveillance, surgery, brachytherapy, or external beam radiation with or without androgen deprivation therapy for localized prostate cancer","volume":"323","author":"Hoffman","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.euf.2025.06.007_b0020","doi-asserted-by":"crossref","first-page":"435","DOI":"10.7326\/0003-4819-148-6-200803180-00209","article-title":"Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer","volume":"148","author":"Wilt","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.euf.2025.06.007_b0025","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/S1470-2045(22)00251-0","article-title":"MRI-guided focused ultrasound (MRgFUS) focal therapy for intermediate-risk prostate cancer: a phase 2b multicenter study","volume":"23","author":"Ehdaie","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2025.06.007_b0030","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1055\/s-0035-1564793","article-title":"High-intensity focused ultrasound: current status for image-guided therapy","volume":"32","author":"Copelan","year":"2015","journal-title":"Semin Interv Radiol"},{"key":"10.1016\/j.euf.2025.06.007_b0035","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-targeted or standard biopsy for prostate-cancer diagnosis","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2025.06.007_b0040","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.prnil.2024.03.004","article-title":"Propensity score matched analysis of functional outcome in five thousand cases of robot-assisted radical prostatectomy versus high-intensity focused ultrasound","volume":"12","author":"Nam","year":"2024","journal-title":"Prostate Int"},{"key":"10.1016\/j.euf.2025.06.007_b0045","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.eururo.2024.11.006","article-title":"Whole-gland or subtotal high-intensity focused ultrasound versus radical prostatectomy: the prospective, noninferiority, nonrandomized HIFI trial","volume":"87","author":"Ploussard","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.06.007_b0050","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.eururo.2022.01.005","article-title":"Cancer control outcomes following focal therapy using high-intensity focused ultrasound in 1379 men with nonmetastatic prostate cancer: a multi-institute 15-year experience","volume":"81","author":"Reddy","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.06.007_b0055","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.prnil.2022.12.001","article-title":"Partial gland ablation using high-intensity focused ultrasound versus robot-assisted radical prostatectomy: a propensity score-matched study","volume":"11","author":"Jung","year":"2023","journal-title":"Prostate Int"},{"key":"10.1016\/j.euf.2025.06.007_b0060","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3390\/jpm12020251","article-title":"High-intensity focused-ultrasound focal therapy versus laparoscopic radical prostatectomy: a comparison of oncological and functional outcomes in low- and intermediate-risk prostate cancer patients","volume":"12","author":"Nyk","year":"2022","journal-title":"J Pers Med"},{"key":"10.1016\/j.euf.2025.06.007_b0065","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/sj.ijir.3900472","article-title":"Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction","volume":"11","author":"Rosen","year":"1999","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.euf.2025.06.007_b0070","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/S0022-5347(17)36966-5","article-title":"The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association","volume":"148","author":"Barry","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2025.06.007_b0075","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/bju.14452","article-title":"Prolaris gene expression assay for assessing long-term risk of prostate cancer progression","volume":"122","author":"NICE Advice","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2025.06.007_b0080","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1097\/01.ju.0000158155.33890.e7","article-title":"The UCSF Cancer of the Prostate Risk Assessment (CAPRA) Score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy","volume":"173","author":"Cooperberg","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2025.06.007_b0085","doi-asserted-by":"crossref","first-page":"489.e9","DOI":"10.1016\/j.urolonc.2022.07.017","article-title":"Evaluation of post-ablation mpMRI as a predictor of residual prostate cancer after focal high intensity focused ultrasound (HIFU) ablation","volume":"40","author":"Khandwala","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2025.06.007_b0090","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41391-022-00531-8","article-title":"Diagnostic value of multiparametric MRI in detecting residual or recurrent prostate cancer after high-intensity focused ultrasound","volume":"26","author":"Ahn","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euf.2025.06.007_b0095","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/bju.16213","article-title":"Focal therapy with high-intensity focused ultrasound for prostate cancer: 3-year outcomes from a prospective trial","volume":"133","author":"Kaufmann","year":"2024","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2025.06.007_b0100","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1097\/JU.0000000000001934","article-title":"Role of systematic control biopsies following partial gland ablation with high-intensity focused ultrasound for clinically significant prostate cancer","volume":"206","author":"Rompr\u00e9-Brodeur","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2025.06.007_b0105","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.acuro.2016.04.016","article-title":"High intensity focused ultrasound with Focal-One\u00ae device: prostate-specific antigen impact and morbidity evaluation during the initial experience","volume":"40","author":"Perez-Reggeti","year":"2016","journal-title":"Actas Urol Esp"},{"key":"10.1016\/j.euf.2025.06.007_b0110","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.purol.2023.09.012","article-title":"Oncological and functional results of focal treatment of localized prostate cancer with HIFU","volume":"33","author":"Debard","year":"2023","journal-title":"Prog Urol"},{"key":"10.1016\/j.euf.2025.06.007_b0115","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.eururo.2023.06.013","article-title":"Primary whole-gland ablation for the treatment of clinically localized prostate cancer: a focal therapy society best practice statement","volume":"84","author":"Deivasigamani","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.06.007_b0120","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s00345-023-04352-9","article-title":"Single-center, prospective phase 2 trial of high-intensity focused ultrasound (HIFU) in patients with unilateral localized prostate cancer: good functional results but oncologically not as safe as expected","volume":"41","author":"Duwe","year":"2023","journal-title":"World J Urol"},{"key":"10.1016\/j.euf.2025.06.007_b0125","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/JU.0000000000001787","article-title":"Association between lesion location and oncologic outcomes after focal therapy for localized prostate cancer using either high intensity focused ultrasound or cryotherapy","volume":"206","author":"Stabile","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2025.06.007_b0130","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.eururo.2018.06.006","article-title":"A multicentre study of 5-year outcomes following focal therapy in treating clinically significant nonmetastatic prostate cancer","volume":"74","author":"Guillaumier","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.06.007_b0135","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3109\/21681805.2014.988174","article-title":"High-intensity focused ultrasound for the treatment of prostate cancer: a prospective trial with long-term follow-up","volume":"49","author":"Mearini","year":"2015","journal-title":"Scand J Urol"},{"key":"10.1016\/j.euf.2025.06.007_b0140","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/bju.16122","article-title":"Prostate cancer outcomes following whole-gland and focal high-intensity focused ultrasound","volume":"132","author":"Parry","year":"2023","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2025.06.007_b0145","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/iju.13581","article-title":"Primary whole-gland ablation for localized prostate cancer with high-intensity focused ultrasound: The important predictors of biochemical recurrence","volume":"25","author":"Chen","year":"2018","journal-title":"Int J Urol"},{"key":"10.1016\/j.euf.2025.06.007_b0150","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.euo.2018.12.007","article-title":"Validation of the Decipher test for predicting distant metastatic recurrence in men with high-risk nonmetastatic prostate cancer 10 years after surgery","volume":"2","author":"Van den Broeck","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euf.2025.06.007_b0155","doi-asserted-by":"crossref","unstructured":"Ghoreifi A, Gomella L, Hu JC, et al. Identifying the best candidate for focal therapy: a comprehensive review. Prostate Cancer Prostatic Dis (in press). https:\/\/doi.org\/10.1038\/s41391-024-00907-y.","DOI":"10.1038\/s41391-024-00907-y"},{"key":"10.1016\/j.euf.2025.06.007_b0160","doi-asserted-by":"crossref","first-page":"e409","DOI":"10.1097\/01.JU.0001008692.26556.39.12","article-title":"MP25-12 utilizing the genomic prostate score (GPS) as a prognostic biomarker in patients with localized prostate cancer undergoing focal therapy","volume":"211","author":"Deivasigamani","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2025.06.007_b0165","doi-asserted-by":"crossref","first-page":"S1535","DOI":"10.1016\/j.annonc.2024.10.365","article-title":"346P High genomic risk is associated with clinically significant prostate cancer (csPCa) recurrences following focal therapy (FT)","volume":"35","author":"Hong","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euf.2025.06.007_b0170","article-title":"Focal cryoablation of the prostate: primary treatment in 163 patients with localized prostate cancer","volume":"15","author":"Khan","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.euf.2025.06.007_b0175","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1590\/s1677-5538.ibju.2021.0091","article-title":"Available evidence on HIFU for focal treatment of prostate cancer: a systematic review","volume":"48","author":"Bakavicius","year":"2022","journal-title":"Int Braz J Urol"},{"key":"10.1016\/j.euf.2025.06.007_b0180","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41391-021-00390-9","article-title":"Oncological and functional outcome after partial prostate HIFU ablation with Focal-One\u00ae: a prospective single-center study","volume":"24","author":"Dellabella","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euf.2025.06.007_b0185","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1148\/radiol.2021202717","article-title":"MRI-guided focused ultrasound ablation for localized intermediate-risk prostate cancer: early results of a phase II trial","volume":"298","author":"Ghai","year":"2021","journal-title":"Radiology"},{"key":"10.1016\/j.euf.2025.06.007_b0190","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00345-024-04840-6","article-title":"High-intensity focused ultrasound with visually directed power adjustment for focal treatment of localized prostate cancer: systematic review and meta-analysis","volume":"42","author":"Peretsman","year":"2024","journal-title":"World J Urol"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456925001749?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456925001749?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T22:12:13Z","timestamp":1765404733000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456925001749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2405456925001749"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2025.06.007","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Determining Optimal Patient Selection for High-intensity Focused Ultrasound for Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2025.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}